Monday, August 3, 2020
Tags Medical regulatory issues

Tag: medical regulatory issues

FDA works to speed coronavirus tests with Roche, New York approvals

ZURICH/NEW YORK (Reuters) - The U.S. Food and Drug Administration (FDA) issued emergency authorization for a faster coronavirus test made by Swiss diagnostics maker...

Exclusive: J&J’s own expert, working for FDA, found asbestos in Baby...

(Reuters) - Ever since Johnson & Johnson disclosed this month that a government test had turned up asbestos in its Baby Powder, the company...

J&J says new tests find no asbestos in same baby powder...

(Reuters) - Johnson & Johnson said on Tuesday that 15 new tests found no asbestos in a bottle of baby powder that the U.S....

Two charities to pay $6 million to resolve U.S. pharma kickback...

BOSTON (Reuters) - Two charities will pay $6 million to resolve claims they operated as pass-throughs for seven pharmaceutical companies to pay kickbacks to...

Big U.S. retailers pull 22-ounce J&J baby powder off shelves after...

(Reuters) - Four major U.S. retailers, including Walmart and Target Corp, are removing all 22-ounce bottles of Johnson & Johnson's baby powder from their...

Walmart pulls 22-ounce J&J baby powder from shelves – CNBC

(Reuters) - Walmart Inc has removed and blocked sales of Johnson & Johnson's 22-ounce baby powder bottles from its stores, CNBC reported...

FTC staff recommends approval of Roche deal for Spark: report

WASHINGTON (Reuters) - The Federal Trade Commission staff reviewing Roche's () plan to buy U.S.-based gene therapy specialist Spark Therapeutics ONCE.O for...

Biogen, Eisai revive plans for Alzheimer’s drug, surprising market

(Reuters) - Biogen Inc () revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more...

Johnson & Johnson CEO testified Baby Powder was safe 13 days...

LOS ANGELES/NEW YORK (Reuters) - Facing off against a plaintiff's lawyer for the first time about Johnson & Johnson's Baby Powder, the company's Chief...

Drug firms avert landmark opioid trial as talks on $48-billion settlement...

CLEVELAND (Reuters) - Four large drug companies could resume talks on Tuesday to try to reach a $48 billion settlement of all opioid litigation...